awmsg logo



golimumab (Simponi®)


Reference No. 1562

Publication date:
05/10/2016


Appraisal information

golimumab (Simponi®) 50 mg solution for injection
golimumab (Simponi®) 100 mg solution for injection


Company: Merck Sharp & Dohme Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: 20/07/2016
AWMSG meeting date: 21/09/2016
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 2316
Ministerial ratification: 04/10/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (ID903) NICE GUIDANCE ISSUED NOVEMBER 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download
Final Appraisal Recommendation (FAR)
Download